News
Javelin Pharmaceuticals CEO to Present at Cowen & Company's 28th Annual Health Care Conference
CAMBRIDGE, Mass.-(Business Wire)-March 14, 2008 - Javelin Pharmaceuticals, Inc. (Amex: JAV) today announced that CEO Martin J. Driscoll will present a corporate overview to investors at the 28th Annual Cowen & Company Health Care conference. Mr. Driscoll's presentation will take place on Monday, March 17, 2008 at 4:00pm in the Regis Room on the Third Floor at the Boston Marriott Copley Place.
The presentation will be webcast live and can be accessed by pasting the following link in to your web browser: www.corporate-ir.net/ireye/confLobby.zhtml?ticker=JAV&item_id=1786587
Listeners are advised to visit the link in advance in order to register and download any necessary software. The event will be archived and available for replay for 90 days.
About Javelin Pharmaceuticals, Inc.
With corporate headquarters in Cambridge, MA, Javelin applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs to target unmet and underserved medical needs in the pain management market. The Company has three drug candidates in US Phase 3 clinical development. One of these US Phase 3 drug candidates, Dyloject(TM), has received Marketing Authorization Application (MAA) approval and favorable pricing in the UK, where it is now being sold. Previous clinical trials have demonstrated its safety and rapid onset of action. For additional information about Javelin, please visit the company's website at http://www.javelinpharmaceuticals.com.
Forward Looking Statement
This news release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, our ability to obtain working capital, our ability to successfully develop and commercialize drug candidates, and competition from other pharmaceutical companies.
JAV-G
Search Our News Using Google Search
Can't find what you want? Try using Google:
